#USA #San Francisco #Field Medical #FieldForce #cardiac ablation

Field Medical's Upcoming Presentation at J.P. Morgan

Field Medical Inc., a clinical-stage medical technology company, is poised to showcase its cutting-edge FieldForce™ Pulsed Field Ablation (PFA) platform at the prestigious 44th Annual Healthcare Conference hosted by J.P. Morgan in San Francisco. Founder Dr. Steven Mickelsen will present the latest insights and developments on January 15, 2026, at 10 a.m. Pacific Time.

Introduction to Field Medical

Founded in 2022, Field Medical is revolutionizing the treatment of complex cardiac arrhythmias through innovative technology. The company specializes in developing PFA solutions aimed at conditions such as Ventricular Tachycardia (VT) and Atrial Fibrillation (AF). The FieldForce™ PFA system uses state-of-the-art technology to create transmural lesions, offering a novel approach to ablation therapy.

What to Expect at the Conference

During the presentation, Dr. Mickelsen will provide a comprehensive overview of Field Medical, including:

• - The innovative design and capabilities of the FieldForce™ PFA platform.
• - Recent clinical progress in treating VT via the pioneering Field-PULSE AF study.
• - Details regarding upcoming critical clinical trials focused on VT.

The management team will also be available for meetings throughout the conference, providing a unique opportunity for interested investors and healthcare professionals to discuss the company's vision and future plans. To arrange a meeting with the Field Medical team, attendees are encouraged to contact [email protected].

Advancements in Cardiac Care

The technology at the heart of the FieldForce™ system combines a focal catheter design with proprietary FieldBending™ energy delivery, ensuring precision and efficiency during the ablation process. This innovative approach aims to enhance safety and improve patient outcomes in treating both ventricular and atrial arrhythmias.

Field Medical's commitment to pushing the boundaries of cardiac care was recognized in 2024 when it received the designation of an Innovative Device and joined the FDA's Pilot TAP Program for its VT indication. Following the successful publication of findings from the VCAS trial in the journal Circulation in October 2025, the company continues to make strides in clinical research and application.

Conclusion

As Field Medical prepares to share its advancements at the J.P. Morgan Healthcare Conference, the medical community eagerly anticipates the innovations that may redefine cardiac ablation therapies. With a focus on safety, efficacy, and improved outcomes, Field Medical stands at the forefront of transforming how complex arrhythmias are treated, paving the way for future breakthroughs in cardiac care. For additional insights and updates, visit Field Medical’s website and follow them on LinkedIn, X, and YouTube. The FieldForce™ Ablation System is an investigational device whose use is restricted by federal law to investigational use only.

Media and Investor Relations Contacts

For press inquiries, please contact Holly Windler at 619.929.1275 or [email protected]. For investor relations, reach out to [email protected].